We read with great interest the article titled “New genetic drivers in hemorrhagic hereditary telangiectasia’, recently published in the European Journal of Internal Medicine. Cerdà and colleagues eloquently describe how genetic mutations cause arteriovenous malformation (AVM) formation [1]. As Hereditary Hemorrhagic Telangiectasia (HHT) is characterized by epistaxis and AVMs, we recognize the burden on the patient's quality of life [1]. Regarding their paper, we acknowledge that genetic variants may be causing AVM formation, and we believe targeting gene mutations causing HHT may be fruitful.
